Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)

• Company Description    Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $0.82 Daily Weekly Monthly 20 Day Moving Average: 410,109 shares Shares Outstanding: 23.27 (millions) Market Capitalization: $19.08 (millions) Beta: -0.31 52 Week High: $1.80 52 Week Low: $0.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.00% -20.10% 12 Week 41.41% 30.73% Year To Date 62.10% 31.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1951 NW 7TH AVENUE SUITE 520 - MIAMI,FL 33136 USA ph: 305-909-0840 fax: - investorrelations@longeveron.com https://longeveron.com

• General Corporate Information    Officers Stephen H. Willard - Chief Executive Officer Joshua M. Hare - Co-Founder; Chief Science Officer; Executive Chair Lisa A. Locklear - Chief Financial Officer and Treasurer George Paletta, Jr - Director Roger Hajjar - Director Peer Information Longeveron Inc. (CORR.) Longeveron Inc. (RSPI) Longeveron Inc. (CGXP) Longeveron Inc. (BGEN) Longeveron Inc. (GTBP) Longeveron Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 54303L203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 23.27 Most Recent Split Date: 3.00 (0.10:1) Beta: -0.31 Market Capitalization: $19.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.68 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.19 Price/Cash Flow: - Price / Sales: 15.69 EPS Growth vs. Year Ago Period: 44.12% vs. Previous Quarter: 13.64% Sales Growth vs. Year Ago Period: 4.46% vs. Previous Quarter: 9.04% ROE 03/31/26 - -202.41 12/31/25 - -199.79 09/30/25 - -138.44 ROA 03/31/26 - -140.67 12/31/25 - -143.21 09/30/25 - -108.46 Current Ratio 03/31/26 - 3.88 12/31/25 - 1.33 09/30/25 - 2.09 Quick Ratio 03/31/26 - 3.88 12/31/25 - 1.33 09/30/25 - 2.09 Operating Margin 03/31/26 - -1,844.49 12/31/25 - -1,893.58 09/30/25 - -1,485.25 Net Margin 03/31/26 - -1,844.49 12/31/25 - -1,893.58 09/30/25 - -1,485.25 Pre-Tax Margin 03/31/26 - -1,844.49 12/31/25 - -1,893.58 09/30/25 - -1,485.25 Book Value 03/31/26 - 0.69 12/31/25 - 0.25 09/30/25 - 0.47 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.05 12/31/25 - 0.03 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 4.63 12/31/25 - 2.89 09/30/25 - 0.00

Powered by Zacks Investment Research ©